Activation of DREAM (Downstream Regulatory Element Antagonistic Modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice

Biological Psychiatry

Volumn 77, Issue 2, 2015, Pages 95-105

  Ruiz Dediego, Irene ^a,d   Mellstrom, Britt ^b,d   Vallejo, Mario ^c,e   Naranjo, Jose R ^b,d   Moratalla, Rosario ^a,d  

^a INSTITUTO CAJAL   (Spain)

^b CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^c INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Abnormal involuntary movements; Dopaminergic denervation; Dynorphin B; FosB; Parkinson's disease; Phospho GluR1

Indexed keywords

CALCIUM BINDING PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOWNSTREAM REGULATORY ELEMENT ANTAGONISTIC MODULATOR; DYNORPHIN B; GLUTAMATE RECEPTOR 1; HISTONE H3; LEVODOPA; OXIDOPAMINE; PROTEIN C FOS; TRANSCRIPTION FACTOR FRA 2; UNCLASSIFIED DRUG; AMPA RECEPTOR; ANTIPARKINSON AGENT; CSEN PROTEIN, MOUSE; DYNORPHIN; ENDORPHIN; FOSB PROTEIN, MOUSE; GLUTAMATE RECEPTOR IONOTROPIC, AMPA 1; HISTONE; KV CHANNEL INTERACTING PROTEIN; REPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYLINDER TEST; DRUG EFFICACY; DYSKINESIA; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MOTOR COORDINATION; MOUSE; NERVE CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; ACETYLATION; ANIMAL; CORPUS STRIATUM; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; METABOLISM; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; ROTAROD TEST;

ACETYLATION; ANIMALS; ANTIPARKINSON AGENTS; BLOTTING, WESTERN; CORPUS STRIATUM; DYNORPHINS; DYSKINESIA, DRUG-INDUCED; ENDORPHINS; HISTONES; IMMUNOHISTOCHEMISTRY; KV CHANNEL-INTERACTING PROTEINS; LEVODOPA; MICE, KNOCKOUT; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSONIAN DISORDERS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-FOS; RECEPTORS, AMPA; REPRESSOR PROTEINS; ROTAROD PERFORMANCE TEST;

EID: 84918825649     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2014.03.023     Document Type: Article

References (72)

1. N. Pavón, A.B. Martín, A. Mendialdua, and R. Moratalla ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice Biol Psychiatry 59 2006 64 74
2. M.G. Murer, and R. Moratalla Striatal signaling in L-DOPA-induced dyskinesia: Common mechanisms with drug abuse and long term memory involving D1 dopamine receptor stimulation Front Neuroanat 5 2011 51
3. M. Delfino, R. Kalisch, M. Czisch, C. Larramendy, J. Ricatti, and I.R. Taravini Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging Neuropsychopharmacology 32 2007 1911 1921
4. M. Lebel, L. Chagniel, G. Bureau, and M. Cyr Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat Neurobiol Dis 38 2010 59 67
5. G. Fisone, and E. Bezard Molecular mechanisms of L-DOPA-induced dyskinesia Int Rev Neurobiol 98 2011 95 122
6. E. Santini, E. Valjent, A. Usiello, M. Carta, A. Borgkvist, and J.A. Girault Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia J Neurosci 27 2007 6995 7005
7. E. Santini, M. Feyder, G. Gangarossa, H.S. Bateup, P. Greengard, and G. Fisone Dopamine- and cAMP-regulated phosphoprotein of 32-kDa (DARPP-32)-dependent activation of extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin complex 1 (mTORC1) signaling in experimental parkinsonism J Biol Chem 287 2012 27806 27812
8. S. Schuster, A. Nadjar, J.T. Guo, Q. Li, C. Ittrich, and B. Hengerer The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease J Neurosci 28 2008 4311 4316
9. S. Fasano, E. Bezard, A. D'Antoni, V. Francardo, M. Indrigo, and L. Qin Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia Proc Natl Acad Sci U S A 107 2010 21824 21829
10. S. Darmopil, A.B. Martín, I.R. De Diego, S. Ares, and R. Moratalla Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation Biol Psychiatry 66 2009 603 613
11. E. Santini, C. Alcacer, S. Cacciatore, M. Heiman, D. Hervé, and P. Greengard L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice J Neurochem 108 2009 621 633
12. T.N. Chase, J.D. Oh, and S. Konitsiotis Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms J Neurol 247 suppl 2 2000 II36 II42
13. P.J. Hallett, A.W. Dunah, P. Ravenscroft, S. Zhou, E. Bezard, and A.R. Crossman Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease Neuropharmacology 48 2005 503 516
14. F. Gardoni, B. Picconi, V. Ghiglieri, F. Polli, V. Bagetta, and G. Bernardi A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia J Neurosci 26 2006 2914 2922
15. M.A. Silverdale, C. Kobylecki, P.J. Hallett, Q. Li, A.W. Dunah, and P. Ravenscroft Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate Synapse 64 2010 177 180
16. A. Berthet, G. Porras, E. Doudnikoff, H. Stark, M. Cador, and E. Bezard Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia J Neurosci 29 2009 4829 4835
17. J.E. Nash, T.H. Johnston, G.L. Collingridge, C.C. Garner, and J.M. Brotchie Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia FASEB J 19 2005 583 585
18. G. Porras, A. Berthet, B. Dehay, Q. Li, L. Ladepeche, and E. Normand PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking J Clin Invest 122 2012 3977 3989
19. D.J. Surmeier, J. Bargas, H.C. Hemmings Jr, A.C. Nairn, and P. Greengard Modulation of calcium currents by a D1 dopaminergic protein kinase/phosphatase cascade in rat neostriatal neurons Neuron 14 1995 385 397
20. S. Schuster, E. Doudnikoff, D. Rylander, A. Berthet, I. Aubert, and C. Ittrich Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia Biol Psychiatry 65 2009 518 526
21. F. Ledo, W.A. Link, A.M. Carrión, V. Echeverria, B. Mellström, and J.R. Naranjo The DREAM-DRE interaction: key nucleotides and dominant negative mutants Biochim Biophys Acta 1498 2000 162 168
22. B. Cebolla, A. Fernández-Pérez, G. Perea, A. Araque, and M. Vallejo DREAM mediates cAMP-dependent, Ca2+-induced stimulation of GFAP gene expression and regulates cortical astrogliogenesis J Neurosci 28 2008 6703 6713
23. F. Spreafico, J.J. Barski, C. Farina, and M. Meyer Mouse DREAM/calsenilin/KChIP3: Gene structure, coding potential, and expression Mol Cell Neurosci 17 2001 1 16
24. H. Xiong, I. Kovacs, and Z. Zhang Differential distribution of KChIPs mRNAs in adult mouse brain Brain Res Mol Brain Res 128 2004 103 111
25. C.E. Duncan, P.R. Schofield, and C.S. Weickert K(v) channel interacting protein 3 expression and regulation by haloperidol in midbrain dopaminergic neurons Brain Res 1304 2009 1 13
26. A.M. Carrión, W.A. Link, F. Ledo, B. Mellström, and J.R. Naranjo DREAM is a Ca2+-regulated transcriptional repressor Nature 398 1999 80 84
27. W.A. Link, F. Ledo, B. Torres, M. Palczewska, T.M. Madsen, and M. Savignac Day-night changes in downstream regulatory element antagonist modulator/potassium channel interacting protein activity contribute to circadian gene expression in pineal gland J Neurosci 24 2004 5346 5355
28. F. Ledo, A.M. Carrión, W.A. Link, B. Mellström, and J.R. Naranjo DREAM-alphaCREM interaction via leucine-charged domains derepresses downstream regulatory element-dependent transcription Mol Cell Biol 20 2000 9120 9126
29. F. Ledo, L. Kremer, B. Mellström, and J.R. Naranjo Ca2+-dependent block of CREB-CBP transcription by repressor DREAM EMBO J 21 2002 4583 4592
30. M. Osawa, K.I. Tong, C. Lilliehook, W. Wasco, J.D. Buxbaum, and H.Y. Cheng Calcium-regulated DNA binding and oligomerization of the neuronal calcium-sensing protein, calsenilin/DREAM/KChIP3 J Biol Chem 276 2001 41005 41013
31. M. Rivas, D. Villar, P. González, X.M. Dopazo, B. Mellstrom, and J.R. Naranjo Building the DREAM interactome Sci China Life Sci 54 2011 786 792
32. Y. Zhang, P. Su, P. Liang, T. Liu, X. Liu, and X.Y. Liu The DREAM protein negatively regulates the NMDA receptor through interaction with the NR1 subunit J Neurosci 30 2010 7575 7586
33. L.J. Wu, B. Mellström, H. Wang, M. Ren, S. Domingo, and S.S. Kim DREAM (downstream regulatory element antagonist modulator) contributes to synaptic depression and contextual fear memory Mol Brain 3 2010 3
34. R. Gomez-Villafuertes, B. Torres, J. Barrio, M. Savignac, N. Gabellini, and F. Rizzato Downstream regulatory element antagonist modulator regulates Ca2+ homeostasis and viability in cerebellar neurons J Neurosci 25 2005 10822 10830
35. M. Savignac, B. Pintado, A. Gutierrez-Adan, M. Palczewska, B. Mellström, and J.R. Naranjo Transcriptional repressor DREAM regulates T-lymphocyte proliferation and cytokine gene expression EMBO J 24 2005 3555 3564
36. H.Y. Cheng, G.M. Pitcher, S.R. Laviolette, I.Q. Whishaw, K.I. Tong, and L.K. Kockeritz DREAM is a critical transcriptional repressor for pain modulation Cell 108 2002 31 43
37. M. Mayford, M.E. Bach, Y.Y. Huang, L. Wang, R.D. Hawkins, and E.R. Kandel Control of memory formation through regulated expression of a CaMKII transgene Science 274 1996 1678 1683
38. L.M. Suárez, O. Solís, J.M. Caramés, I.R. Taravini, J.M. Solís, and M.G. Murer L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice [published online ahead of print Jun 12] Biol Psychiatry. 2013
39. S. Darmopil, V.C. Muñetón-Gómez, M.L. de Ceballos, M. Bernson, and R. Moratalla Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA Eur J Neurosci 27 2008 580 592
40. N. Granado, O. Ortiz, L.M. Suárez, E.D. Martín, V. Ceña, and J.M. Solís D1 but not D5 dopamine receptors are critical for LTP, spatial learning, and LTP-induced arc and zif3268 expression in the hippocampus Cereb Cortex 18 2008 1 12
41. R. González-Aparicio, and R. Moratalla Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson's disease Neurobiol Dis 62 2014 416 425
42. I. Espadas, S. Darmopil, E. Vergaño-Vera, O. Ortiz, I. Oliva, and C. Vicario-Abejón L-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: Insights into regulation and function Neurobiol Dis 48 2012 271 281
43. S. Ares-Santos, N. Granado, I. Oliva, E. O'Shea, E.D. Martin, and M.I. Colado Dopamine D(1) receptor deletion strongly reduces neurotoxic effects of methamphetamine Neurobiol Dis 45 2012 810 820
44. S. Ares-Santos, N. Granado, I. Espadas, R. Martinez-Murillo, and R. Moratalla Methamphetamine causes degeneration of dopamine cell bodies and terminals of the nigrostriatal pathway evidenced by silver staining Neuropsychopharmacology 39 2014 1066 1080
45. N. Granado, I. Escobedo, E. O'Shea, I. Colado, and R. Moratalla Early loss of dopaminergic terminals in striosomes after MDMA administration to mice Synapse 62 2008 80 84
46. -ΔΔCT method Methods 25 2001 402 408
47. V. Francardo, A. Recchia, N. Popovic, D. Andersson, H. Nissbrandt, and M.A. Cenci Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease Neurobiol Dis 42 2011 327 340
48. M. Andersson, A. Hilbertson, and M.A. Cenci Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease Neurobiol Dis 6 1999 461 474
49. E. Santini, V. Sgambato-Faure, Q. Li, M. Savasta, S. Dovero, and G. Fisone Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia PLoS One 5 2010 e12322
50. J.C. Alexander, C.M. McDermott, T. Tunur, V. Rands, C. Stelly, and D. Karhson The role of calsenilin/DREAM/KChIP3 in contextual fear conditioning Learn Mem 16 2009 167 177
51. M. Dierssen, L. Fedrizzi, R. Gomez-Villafuertes, M.M. de Lagran, A. Gutierrez-Adan, and I. Sahún Reduced Mid1 expression and delayed neuromotor development in daDREAM transgenic mice Front Mol Neurosci 5 2012 58
52. J.R. Naranjo, and B. Mellström Ca2+-dependent transcriptional control of Ca2+ homeostasis J Biol Chem 287 2012 31674 31680
53. P. Piccini, R.A. Weeks, and D.J. Brooks Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias Ann Neurol 42 1997 720 726
54. P.K. Tekumalla, F. Calon, Z. Rahman, S. Birdi, A.H. Rajput, and O. Hornykiewicz Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson's disease Biol Psychiatry 50 2001 813 816
55. O. Berton, C. Guigoni, Q. Li, B.H. Bioulac, I. Aubert, and C.E. Gross Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease Biol Psychiatry 66 2009 554 561
56. M.K. Tamim, P. Samadi, M. Morissette, L. Grégoire, B. Ouattara, and D. Lévesque Effect of non-dopaminergic drug treatment on levodopa induced dyskinesias in MPTP monkeys: Common implication of striatal neuropeptides Neuropharmacology 58 2010 286 296
57. P.S. Lazo, K. Dorfman, T. Noguchi, M.G. Mattéi, and R. Bravo Structure and mapping of the fosB gene. FosB downregulates the activity of the fosB promoter Nucleic Acids Res 20 1992 343 350
58. R. Moratalla, M. Xu, S. Tonegawa, and A.M. Graybiel Cellular responses to psychomotor stimulant and neuroleptic drugs are abnormal in mice lacking the D1 dopamine receptor Proc Natl Acad Sci U S A 93 1996 14928 14933
59. J.R. Naranjo, B. Mellström, M. Achaval, and P. Sassone-Corsi Molecular pathways of pain: Fos/Jun-mediated activation of a noncanonical AP-1 site in the prodynorphin gene Neuron 6 1991 607 617
60. W.F. An, M.R. Bowlby, M. Betty, J. Cao, H.P. Ling, and G. Mendoza Modulation of A-type potassium channels by a family of calcium sensors Nature 403 2000 553 556
61. M. Rivas, B. Mellström, B. Torres, G. Cali, A.M. Ferrara, and D. Terracciano The DREAM Protein is associated to thyroid enlargement and nodular development Mol Endocrinol 23 2009 862 870
62. Y. Zhang, G.E. Meredith, N. Mendoza-Elias, D.J. Rademacher, K.Y. Tseng, and K. Steece-Collier Aberrant restoration of spines and their synapses in L-DOPA-induced dyskinesia: Involvement of corticostriatal but not thalamostriatal synapses J Neurosci 33 2013 11655 11667
63. S.M. Papa, R.C. Boldry, T.M. Engber, A.M. Kask, and T.N. Chase Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade Brain Res 701 1995 13 18
64. P.J. Blanchet, L.V. Metman, and T.N. Chase Renaissance of amantadine in the treatment of Parkinson's disease Adv Neurol 91 2003 251 257
65. I.F. Harrison, and D.T. Dexter Epigenetic targeting of histone deacetylase: Therapeutic potential in Parkinson's disease? Pharmacol Ther 140 2013 34 52
66. P. Cheung, K.G. Tanner, W.L. Cheung, P. Sassone-Corsi, J.M. Denu, and C.D. Allis Synergistic coupling of histone H3 phosphorylation and acetylation in response to epidermal growth factor stimulation Mol Cell 5 2000 905 915
67. C. Alcacer, E. Santini, E. Valjent, F. Gaven, J.A. Girault, and D. Hervé Gα(olf) mutation allows parsing the role of cAMP-dependent and extracellular signal-regulated kinase-dependent signaling in L-3,4-dihydroxyphenylalanine-induced dyskinesia J Neurosci 32 2012 5900 5910
68. R. Malinow, Z.F. Mainen, and Y. Hayashi LTP mechanisms: From silence to four-lane traffic Curr Opin Neurobiol 10 2000 352 357
69. R.C. Malenka Synaptic plasticity and AMPA receptor trafficking Ann N Y Acad Sci 1003 2003 1 11
70. J.D. Shepherd, and R.L. Huganir The cell biology of synaptic plasticity: AMPA receptor trafficking Annu Rev Cell Dev Biol 23 2007 613 643
71. M.B. Thomsen, C. Wang, N. Ozgen, H.G. Wang, M.R. Rosen, and G.S. Pitt Accessory subunit KChIP2 modulates the cardiac L-type calcium current Circ Res 104 2009 1382 1389
72. D. Anderson, W.H. Mehaffey, M. Iftinca, R. Rehak, J.D. Engbers, and S. Hameed Regulation of neuronal activity by Cav3-Kv4 channel signaling complexes Nat Neurosci 13 2010 333 337